IAA Journal of Biological Sciences 13(2):111-118, 2025
©IAAJOURNALS
https://doi.org/10.59298/IAAJB/2025/132111118
www.iaajournals.org
ISSN:2636-7254
IAAJB132

Browning of White Adipose Tissue by Natural Compounds: Implications for Obesity-Driven Type 2 Diabetes

Nasira A. Sitar

Department of Pharmacy Kampala International University Uganda
Satar.nasira@studwc.kiu.ac.ug

ABSTRACT

Obesity-driven type 2 diabetes mellitus (T2DM) is a global health challenge characterized by insulin resistance, chronic inflammation, and impaired glucose metabolism. White adipose tissue (WAT) accumulation and dysfunction are central to the pathogenesis of obesity and T2DM. Browning of WAT, a process in which white adipocytes acquire features of thermogenically active brown adipocytes, represents a promising therapeutic target for metabolic disorders. Browning enhances energy expenditure and improves glucose homeostasis via increased mitochondrial activity and expression of uncoupling protein 1 (UCP1). Natural compounds, including polyphenols, flavonoids, and other bioactive phytochemicals, have emerged as potent inducers of WAT browning, exerting beneficial effects on obesity and associated metabolic dysfunctions. This review comprehensively discusses the molecular mechanisms underlying WAT browning, highlights key natural compounds capable of promoting this process, and evaluates their potential implications in managing obesity-driven T2DM. Understanding these natural agents' roles may pave the way for novel, safe, and effective therapeutic strategies targeting adipose tissue plasticity in metabolic diseases.

Keywords: White adipose tissue browning, natural compounds, obesity, type 2 diabetes mellitus, thermogenesis

INTRODUCTION

Obesity and type 2 diabetes mellitus (T2DM) are closely interconnected metabolic disorders that have become global health challenges due to their rising prevalence and associated complications[1–3]. Both conditions are characterized primarily by excess accumulation of adipose tissue, disrupted insulin signaling, and impaired regulation of glucose metabolism. White adipose tissue (WAT), the predominant form of fat in the body, serves as the main reservoir for energy storage by accumulating triglycerides[1, 4]. However, in the state of obesity, WAT undergoes significant pathological changes, including hypertrophy (enlargement of fat cells) and dysfunction[5]. These changes lead to a chronic, low-grade inflammatory state marked by increased secretion of pro-inflammatory cytokines and altered adipokine profiles. Such inflammatory processes contribute to systemic insulin resistance, whereby the body's cells fail to respond effectively to insulin, causing elevated blood glucose levels—a hallmark of T2DM[6, 7]. The dysfunctional WAT thus plays a pivotal role not only in energy imbalance but also in driving the metabolic disturbances that underlie the progression of obesity to insulin resistance and eventually T2DM.

In contrast to WAT, brown adipose tissue (BAT) functions primarily to dissipate energy rather than store it. BAT is specialized in non-shivering thermogenesis, a process that generates heat by burning calories, which is largely mediated by the presence of uncoupling protein 1 (UCP1) in its abundant mitochondria[8]. This unique ability of BAT to convert stored chemical energy into heat contributes significantly to overall energy expenditure and helps maintain metabolic homeostasis[8]. The presence and activity of BAT are inversely correlated with body mass index and metabolic disease risk, indicating its protective role against obesity and related metabolic dysfunctions. Moreover, BAT activation has been shown to improve insulin sensitivity and glucose metabolism, positioning it as an attractive target for therapeutic strategies aimed at combating metabolic diseases. Despite its potential, BAT is relatively scarce in adult humans compared to WAT, which limits its direct impact on energy balance and metabolism[9].

Emerging research has identified a fascinating process whereby certain white adipocytes can convert into beige or brite adipocytes, which exhibit characteristics similar to brown adipocytes, including UCP1 expression and thermogenic capacity[10]. This phenomenon, referred to as "browning" of white adipose tissue, represents a significant paradigm shift in understanding adipose tissue plasticity and its metabolic potential[10]. Browning enhances energy expenditure and insulin sensitivity, offering a promising strategy to counteract obesity and T2DM by increasing the body's capacity to burn excess calories and improve glucose regulation[9, 11]. Recent studies have focused on identifying natural compounds and bioactive molecules capable of inducing WAT browning, which could be harnessed as safer and more accessible therapeutic options[12]. These compounds, derived from plants, foods, and other natural sources, may activate key molecular pathways involved in thermogenesis and mitochondrial biogenesis within adipocytes. This review aims to explore the mechanisms by which natural compounds promote WAT browning, assess their efficacy in experimental models, and discuss their potential implications for managing obesity-driven T2DM, highlighting the growing interest in leveraging adipose tissue plasticity for metabolic health interventions.

White Adipose Tissue Browning: Mechanisms and Significance

Adipose Tissue Types and Plasticity

Adipose tissue is a dynamic and metabolically active organ that plays crucial roles in energy homeostasis, endocrine function, and thermoregulation[13, 14]. It primarily exists in two major forms: white adipose tissue (WAT) and brown adipose tissue (BAT), each with distinct morphological and functional characteristics[15, 16]. WAT is the predominant form in adults and serves mainly as an energy reservoir. It is composed of large adipocytes containing a single, large unilocular lipid droplet that occupies most of the cell volume[17, 18]. These adipocytes have relatively few mitochondria and limited oxidative capacity, reflecting their primary role in storing triglycerides for energy release during periods of caloric deficit. WAT also functions as an endocrine organ, secreting adipokines such as leptin, adiponectin, and inflammatory cytokines, which influence systemic metabolism. In contrast, BAT is specialized for energy dissipation through non-shivering thermogenesis. Brown adipocytes contain multiple small, multilocular lipid droplets and a high density of mitochondria, which are enriched with uncoupling protein 1 (UCP1)[19, 20]. UCP1 uncouples oxidative phosphorylation from ATP production, allowing protons to re-enter the mitochondrial matrix without generating ATP and instead releasing energy as heat. This thermogenic process is vital for maintaining body temperature, especially in neonates and during cold exposure in adults[20, 21]. In addition to classical WAT and BAT, there is a third category of adipocytes known as beige or brite (brown-in-white) adipocytes. These cells reside within WAT depots but can acquire thermogenic properties under specific stimuli such as chronic cold exposure, exercise, or certain hormonal signals. Beige adipocytes express UCP1 and exhibit enhanced mitochondrial biogenesis, thereby increasing energy expenditure and contributing to metabolic health[22, 23]. This plasticity of adipose tissue, the ability of WAT to convert into thermogenically active beige fat, is an area of intense research interest due to its potential for combating obesity and metabolic diseases.

Molecular Mechanisms of Browning

The process of browning, or the conversion of white adipocytes into thermogenically active beige adipocytes, is controlled by a complex network of molecular signaling pathways, transcription factors, and coactivators[24]. Central to this regulation are the peroxisome proliferator-activated receptors (PPARs), particularly PPARγ, which governs adipocyte differentiation and function. PPARγ coactivator-1 alpha (PGC-1α) is a master regulator of mitochondrial biogenesis and oxidative metabolism and plays a pivotal role in initiating the browning program by enhancing the transcriptional activity of PPARγ and other nuclear receptors[24].

PR domain containing 16 (PRDM16) is another crucial transcriptional regulator that determines the thermogenic fate of adipocytes by interacting with PGC-1α and PPARγ to promote brown fat-specific gene expression, including UCP1. PRDM16 is often considered the molecular switch that distinguishes brown and beige adipocyte lineages from white adipocytes[25]. Activation of β-adrenergic receptors by catecholamines such as norepinephrine triggers a signaling cascade starting with the production of cyclic AMP (cAMP) and the activation of protein kinase A (PKA)[25]. PKA phosphorylates downstream targets leading to increased expression of UCP1 and mitochondrial genes, thus promoting thermogenesis. This pathway is fundamental for the acute activation of browning in response to cold or stress[25].

Moreover, energy-sensing pathways such as AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) integrate nutritional and metabolic signals to regulate thermogenic gene expression[26]. AMPK activation enhances fatty acid oxidation and mitochondrial function, while SIRT1 deacetylates and activates PGC-1α, linking cellular energy status to the browning process. Together, these pathways orchestrate a coordinated response that enhances mitochondrial biogenesis, fatty acid metabolism, and uncoupled respiration in beige adipocytes[26].

Natural Compounds Promoting Browning of WAT

Recent research has increasingly focused on natural compounds capable of stimulating the browning of white adipose tissue, as this phenomenon represents a promising therapeutic target for obesity and related metabolic disorders. These bioactive molecules, many derived from plants and dietary sources, modulate key molecular pathways involved in adipocyte differentiation, mitochondrial biogenesis, and thermogenesis, thereby enhancing energy expenditure and improving metabolic health[27–29]. Among these natural compounds, polyphenols have garnered significant attention due to their potent bioactivities and favorable safety profiles. Resveratrol, a stilbene found in grapes, berries, and red wine, is one of the most extensively studied polyphenols[30, 31]. It activates AMPK and SIRT1, thereby promoting mitochondrial biogenesis and increasing UCP1 expression in white adipocytes. This activation enhances thermogenic capacity and has been shown to improve insulin sensitivity and glucose metabolism in various animal models of obesity and diabetes[32, 33]. Curcumin, the principal bioactive compound in turmeric, also induces browning of WAT by upregulating PGC-1α and UCP1[34, 35]. Its effects are partly mediated through activation of AMPK and suppression of pro-inflammatory signaling pathways, which often impair adipose tissue function. Curcumin's anti-inflammatory properties may further support the maintenance of a healthy adipose microenvironment conducive to browning[36]. Epigallocatechin gallate (EGCG), a catechin predominantly found in green tea, exerts thermogenic effects by stimulating β-adrenergic receptor signaling, which increases cAMP levels and activates PKA[26, 37, 38]. This cascade leads to elevated expression of thermogenic genes and enhanced mitochondrial function. EGCG supplementation has been linked to increased energy expenditure and improved glucose homeostasis in both animal studies and human trials. In sum, these natural polyphenols demonstrate significant potential in promoting WAT browning, thereby offering novel dietary or pharmacological strategies to combat obesity and metabolic syndrome.

Flavonoids

Flavonoids are a diverse group of polyphenolic compounds widely found in fruits, vegetables, and other plant-based foods, and they have gained significant attention for their beneficial effects on metabolic health, particularly through the induction of adipose tissue browning[39, 40]. Among these, quercetin and naringenin have been extensively studied for their roles in promoting the browning of white adipose tissue (WAT), a process that enhances energy expenditure and mitigates obesity-related metabolic dysfunctions[41, 42].

Quercetin, a flavonoid abundant in onions, apples, berries, and tea, exerts its browning effects primarily by activating key metabolic regulators such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma (PPARγ)[43]. Activation of AMPK, a cellular energy sensor, stimulates mitochondrial biogenesis and fatty acid oxidation, enhancing thermogenic capacity. PPARγ, a nuclear receptor critical in adipocyte differentiation, further supports the conversion of white adipocytes to a beige phenotype characterized by increased uncoupling protein 1 (UCP1) expression and mitochondrial content[44]. In addition to metabolic activation, quercetin exerts potent antioxidant and anti-inflammatory effects, reducing oxidative stress and chronic inflammation in adipose tissues, which are major contributors to metabolic diseases. These combined actions promote a healthier adipose tissue profile and improved systemic metabolism, suggesting that quercetin-rich diets or supplements could be valuable in obesity and diabetes management[44].

Naringenin, predominantly found in citrus fruits such as oranges, grapefruits, and lemons, also facilitates the browning process by enhancing beige adipocyte differentiation and mitochondrial function[45, 46]. Research has demonstrated that naringenin improves insulin sensitivity by upregulating genes involved in mitochondrial biogenesis and fatty acid oxidation, such as PGC-1α and CPT1[47]. This flavonoid's ability to boost mitochondrial efficiency helps increase energy expenditure, reducing fat accumulation and improving glucose homeostasis. Moreover, naringenin exhibits anti-inflammatory properties by downregulating pro-inflammatory cytokines, thus protecting adipose tissue from inflammation-induced insulin resistance. Its dual action of promoting thermogenesis and improving insulin sensitivity positions naringenin as a promising natural compound for metabolic disease intervention[47].

Together, these flavonoids underscore the therapeutic potential of plant-derived compounds in modulating adipose tissue plasticity and metabolic health. Their multifaceted mechanisms—ranging from molecular signaling to anti-inflammatory effects highlight their utility as adjuncts to lifestyle interventions for combating obesity and type 2 diabetes.

Other Bioactive Compounds

Beyond flavonoids, other bioactive natural compounds such as capsaicin and berberine have demonstrated significant potential in promoting white adipose tissue browning and enhancing metabolic health [16, 48]. These compounds engage distinct molecular targets and pathways, offering complementary mechanisms to flavonoids in mitigating obesity-related disorders. Capsaicin, the spicy alkaloid found in chili peppers, activates the transient receptor potential vanilloid 1 (TRPV1) receptor, a non-selective cation channel expressed in sensory neurons[49]. TRPV1 activation leads to an increase in intracellular calcium, triggering a cascade of events that stimulate the sympathetic nervous system. This sympathetic activation enhances the release of norepinephrine, which binds to β-adrenergic receptors on adipocytes, promoting the browning of white fat through upregulation of thermogenic genes such as UCP1[49]. Capsaicin-induced browning increases energy expenditure and lipid oxidation, contributing to reduced adiposity and improved metabolic profiles. Additionally, capsaicin has been shown to improve glucose metabolism and insulin sensitivity, making it a natural candidate for metabolic syndrome management. Its effects on enhancing fat oxidation and thermogenesis align with the goal of increasing basal metabolic rate and combating obesity-driven metabolic diseases[50]. Berberine, an isoquinoline alkaloid isolated from Berberis species and other medicinal plants, has attracted considerable interest for its broad-spectrum metabolic benefits. Berberine exerts its action primarily by activating AMPK, similar to quercetin, which leads to enhanced glucose uptake, increased fatty acid oxidation, and mitochondrial biogenesis in adipose tissue[51, 52]. The activation of AMPK also stimulates the expression of thermogenic genes such as UCP1 and PGC-1α, promoting the browning of WAT and improving overall energy metabolism. Berberine's ability to improve glucose metabolism extends to reducing hepatic gluconeogenesis and increasing insulin receptor expression, contributing to better glycemic control. Its anti-inflammatory and antioxidant properties further alleviate chronic adipose tissue inflammation, a driver of insulin resistance[53, 54]. Despite its low bioavailability, advances in formulation and delivery are enhancing berberine's clinical applicability. Together, capsaicin and berberine exemplify the diverse molecular targets and pathways through which natural bioactive compounds can induce beneficial browning and metabolic improvements.

Implications for Obesity-Driven Type 2 Diabetes

Obesity-driven type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance, chronic inflammation, and impaired glucose homeostasis[1, 55]. The induction of white adipose tissue browning presents a promising therapeutic strategy to counteract these pathological features by enhancing energy expenditure, improving insulin sensitivity, and reducing inflammation, key factors in T2DM progression and management.

Firstly, browning-induced thermogenesis substantially increases energy expenditure by converting energy-storing white adipocytes into energy-dissipating beige adipocytes rich in mitochondria and UCP1 expression[56]. This increase in basal metabolic rate facilitates weight loss or prevents further weight gain, which is crucial for T2DM management since excess adiposity is a primary driver of insulin resistance. By promoting lipolysis and fatty acid oxidation, browning reduces fat mass, thereby decreasing the metabolic burden on insulin-sensitive tissues such as skeletal muscle and liver. Natural compounds that stimulate browning pathways, such as flavonoids and alkaloids, enhance this energy-dissipating process, providing an additional mechanism to complement diet and exercise interventions. Consequently, the resulting weight management benefits can lower blood glucose levels and improve overall metabolic health[57–59].

Secondly, browning positively influences insulin sensitivity by enhancing glucose uptake and insulin signaling in adipocytes and peripheral tissues. Beige adipocytes exhibit improved mitochondrial function and increased secretion of beneficial adipokines, such as adiponectin, which enhance systemic insulin action[60]. Additionally, natural browning agents mitigate the release of pro-inflammatory cytokines that otherwise impair insulin receptor signaling pathways. This reduction in chronic inflammation further alleviates insulin resistance, which is a hallmark of T2DM[61]. Improved mitochondrial efficiency and reduced oxidative stress in browning adipocytes also contribute to better metabolic flexibility, allowing tissues to switch between glucose and fatty acid oxidation as energy sources. Together, these changes foster enhanced glycemic control and reduce the risk of diabetes-related complications. Lastly, the anti-inflammatory properties of many natural compounds inducing browning play a vital role in T2DM management. Chronic low-grade inflammation in white adipose tissue promotes insulin resistance by activating stress kinases and impairing insulin receptor signaling[60]. Browning agents such as quercetin and berberine reduce oxidative stress and inflammatory cytokine production, restoring adipose tissue homeostasis. This immunomodulatory effect not only improves insulin sensitivity but also protects pancreatic β-cells from inflammatory damage, preserving insulin secretion capacity. Hence, targeting inflammation alongside metabolic pathways offers a comprehensive approach to managing obesity-driven T2DM. In summary, the induction of adipose tissue browning by natural compounds provides multifaceted benefits in combating obesity-associated insulin resistance, offering promising avenues for therapeutic development in T2DM.

Challenges and Future Perspectives

While the preclinical data supporting natural compounds as inducers of white adipose tissue browning and metabolic improvement are promising, significant challenges remain in translating these findings into clinical applications for obesity-driven type 2 diabetes management. A primary challenge is the bioavailability and effective dosing of many natural compounds. Flavonoids like quercetin and naringenin, as well as alkaloids like berberine, often suffer from poor absorption, rapid metabolism, and limited systemic availability when administered orally. This reduces their therapeutic potential despite potent in vitro effects. To overcome this, advanced delivery systems such as nanoparticles, liposomes, or prodrugs are being explored to enhance bioavailability and targeted delivery to adipose tissue. Optimizing dosing regimens to balance efficacy and safety without adverse effects is also essential for clinical success. Furthermore, human clinical studies remain limited and often yield inconsistent results compared to animal models. Differences in metabolism, genetics, and environmental factors make it challenging to replicate the robust browning and metabolic improvements observed in preclinical settings. Large-scale, well-controlled clinical trials are needed to confirm efficacy, establish optimal dosing, and evaluate long-term safety. These studies should include diverse populations to assess the broad applicability of browning agents in metabolic diseases. Another major hurdle is the incomplete mechanistic understanding of how these natural compounds exert their effects in humans. Although key pathways such as AMPK activation and PPARγ modulation are implicated, off-target effects, potential drug interactions, and interindividual variability in response require further elucidation. Detailed molecular investigations will help identify biomarkers predictive of response and safety profiles, enabling personalized treatment approaches. Looking ahead, future research should focus on combinational therapies that synergize different natural compounds or pair them with existing pharmacological agents to enhance efficacy. The development of synthetic analogs with improved potency, stability, and bioavailability also holds promise. Advances in systems biology and precision medicine approaches could allow tailoring browning therapies based on an individual's genetic and metabolic profile, maximizing therapeutic outcomes. While the concept of natural compound-induced adipose tissue browning offers exciting potential for obesity and diabetes treatment, overcoming challenges related to bioavailability, clinical validation, and mechanistic insights is crucial. Continued interdisciplinary research will pave the way for innovative and personalized metabolic therapies that harness adipose tissue plasticity for improved health.

CONCLUSION

Browning of white adipose tissue represents a compelling therapeutic target for combating obesity-driven type 2 diabetes. Natural compounds such as polyphenols, flavonoids, and other phytochemicals demonstrate significant potential to induce browning, enhance thermogenesis, and improve metabolic health. Leveraging these natural agents could lead to innovative, safe, and effective treatments for metabolic disorders, addressing the rising global burden of obesity and T2DM.

REFERENCES

1. Chandrasekaran, P., Weiskirchen, R.: The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. International Journal of Molecular Sciences. 25, 1882 (2024). https://doi.org/10.3390/ijms25031882
2. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obesity Medicine. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
3. Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., Xu, Q.: Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 14, 1161521 (2023). https://doi.org/10.3389/fendo.2023.1161521
4. Anand, S., Patel, T.N.: Integrating the metabolic and molecular circuits in diabetes, obesity and cancer: a comprehensive review. Discov Onc. 15, 779 (2024). https://doi.org/10.1007/s12672-024-01662-1
5. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obesity Medicine. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
6. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
7. Chuah, L.O., Ho, W.Y., Beh, B.K., Yeap, S.K.: Updates on Antiobesity Effect of Garcinia Origin (−)-HCA. Evidence-Based Complementary and Alternative Medicine. 2013, 751658 (2013). https://doi.org/10.1155/2013/751658
8. Bienboire-Frosini, C., Wang, D., Marcet-Rius, M., Villanueva-García, D., Gazzano, A., Domínguez-Oliva, A., Olmos-Hernández, A., Hernández-Ávalos, I., Lezama-García, K., Verduzco-Mendoza, A., Gómez-Prado, J., Mota-Rojas, D.: The Role of Brown Adipose Tissue and Energy Metabolism in Mammalian Thermoregulation during the Perinatal Period. Animals (Basel). 13, 2173 (2023). https://doi.org/10.3390/ani13132173
9. Mulya, A., Kirwan, J.P.: Brown and Beige Adipose Tissue. Endocrinol Metab Clin North Am. 45, 605–621 (2016). https://doi.org/10.1016/j.ecl.2016.04.010
10. Ikeda, K., Maretich, P., Kajimura, S.: The common and distinct features of brown and beige adipocytes. Trends Endocrinol Metab. 29, 191–200 (2018). https://doi.org/10.1016/j.tem.2018.01.001
11. Behzadipour, Y., Hemmati, S.: Covalent conjugation and non-covalent complexation strategies for intracellular delivery of proteins using cell-penetrating peptides. Biomedicine & Pharmacotherapy. 176, 116910 (2024). https://doi.org/10.1016/j.biopha.2024.116910
12. Uti, D.E., Atangwho, I.J., Alum, E.U., Egba, S.I., Ugwu, O.P.-C., Ikechukwu, G.C.: Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 20, 1934578X251323393 (2025). https://doi.org/10.1177/1934578X251323393
13. Ahmed, B., Sultana, R., Greene, M.W.: Adipose tissue and insulin resistance in obese. Biomedicine & Pharmacotherapy. 137, 111315 (2021). https://doi.org/10.1016/j.biopha.2021.111315

14. Chait, A., den Hartigh, L.J.: Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 7, 22 (2020). https://doi.org/10.3389/fcvm.2020.00022
15. Khan, S., Chan, Y.T., Revelo, X.S., Winer, D.A.: The Immune Landscape of Visceral Adipose Tissue During Obesity and Aging. Front Endocrinol (Lausanne). 11, 267 (2020). https://doi.org/10.3389/fendo.2020.00267
16. Hu, X., Zhang, Y., Xue, Y., Zhang, Z., Wang, J.: Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res. 10, 3322–3329 (2018)
17. Im, H., Lee, J., Kim, K., Son, Y., Lee, Y.-H.: Anti-obesity effects of heat-transformed green tea extract through the activation of adipose tissue thermogenesis. Nutrition & Metabolism. 19, 14 (2022). https://doi.org/10.1186/s12986-022-00648-6
18. Hemat Jouy, S., Mohan, S., Scichilone, G., Mostafa, A., Mahmoud, A.M.: Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases. Biomedicines. 12, 2129 (2024). https://doi.org/10.3390/biomedicines12092129
19. Kawai, T., Autieri, M.V., Scalia, R.: Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 320, C375–C391 (2021). https://doi.org/10.1152/ajpcell.00379.2020
20. Nieman, K.M., Romero, I.L., Van Houten, B., Lengyel, E.: Adipose tissue and adipocytes supports tumorigenesis and metastasis. Biochim Biophys Acta. 1831, 1533–1541 (2013). https://doi.org/10.1016/j.bbalip.2013.02.010
21. Jayarathne, S., Koboziev, I., Park, O.-H., Oldewage-Theron, W., Shen, C.-L., Moustaid-Moussa, N.: Anti-Inflammatory and Anti-Obesity Properties of Food Bioactive Components: Effects on Adipose Tissue. Prev Nutr Food Sci. 22, 251–262 (2017). https://doi.org/10.3746/pnf.2017.22.4.251
22. Ruiz-Ojeda, F.J., Méndez-Gutiérrez, A., Aguilera, C.M., Plaza-Díaz, J.: Extracellular Matrix Remodeling of Adipose Tissue in Obesity and Metabolic Diseases. International Journal of Molecular Sciences. 20, 4888 (2019). https://doi.org/10.3390/ijms20194888
23. Queiroz, M., Sena, C.M.: Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health. Cardiovascular Diabetology. 23, 455 (2024). https://doi.org/10.1186/s12933-024-02549-9
24. Inagaki, T., Sakai, J., Kajimura, S.: Transcriptional and epigenetic control of brown and beige adipose cell fate and function. Nat Rev Mol Cell Biol. 17, 480–495 (2016). https://doi.org/10.1038/nrm.2016.62
25. Mao, L., Lu, J., Hou, Y., Nie, T.: Directly targeting PRDM16 in thermogenic adipose tissue to treat obesity and its related metabolic diseases. Front. Endocrinol. 15, (2024). https://doi.org/10.3389/fendo.2024.1458848
26. van der Vaart, J.I., Boon, M.R., Houtkooper, R.H.: The Role of AMPK Signaling in Brown Adipose Tissue Activation. Cells. 10, 1122 (2021). https://doi.org/10.3390/cells10051122
27. Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
28. Agada, S.A., Odama, R.I., Kenechukwu, C.O., Aondoaseer, K., Ezeh, C.O., Uti, D.E., Alum, E.U.: Antioxidant and hepatoprotective effects of methanolic seed extract of Telfairia occidentalis on carbon tetrachloride induced hepatic damage in wistar rats. Discov Med. 1, 75 (2024). https://doi.org/10.1007/s44337-024-00096-6
29. Umoru, G.U., Atangwho, I.J., David-Oku, E., Uti, D.E., De Campos, O.C., Udeozor, P.A., Nfona, S.O., Lawal, B., Alum, E.U.: Modulation of Lipogenesis by Tetracarpidium conophorum Nuts via SREBP-1/ACCA-1/FASN Inhibition in Monosodium-Glutamate-Induced Obesity in Rats. Natural Product Communications. 20, 1934578X251344035 (2025). https://doi.org/10.1177/1934578X251344035
30. Mahjabeen, W., Khan, D.A., Mirza, S.A.: Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complementary Therapies in Medicine. 66, 102819 (2022). https://doi.org/10.1016/j.ctim.2022.102819
31. Alum, E.U.: Role of phytochemicals in cardiovascular disease management: Insights into mechanisms, efficacy, and clinical application. Phytomedicine Plus. 5, 100695 (2025). https://doi.org/10.1016/j.phyplu.2024.100695
32. Wu, S., Wang, L., Wang, F., Zhang, J.: Resveratrol improved mitochondrial biogenesis by activating SIRT1/PGC-1α signal pathway in SAP. Sci Rep. 14, 26216 (2024). https://doi.org/10.1038/s41598-024-76825-9

33. Zheng, S., Deng, R., Huang, G., Ou, Z., Shen, Z.: Effects of honokiol combined with resveratrol on bacteria responsible for oral malodor and their biofilm. J Oral Microbiol. 16, 2361402. https://doi.org/10.1080/20002297.2024.2361402
34. Alam, M.S., Anwar, M.J., Maity, M.K., Azam, F., Jaremko, M., Emwas, A.-H.: The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications. Pharmaceuticals. 17, 1674 (2024). https://doi.org/10.3390/ph17121674
35. Ashtary-Larky, D., Rezaei Kelishadi, M., Bagheri, R., Moosavian, S.P., Wong, A., Davoodi, S.H., Khalili, P., Dutheil, F., Suzuki, K., Asbaghi, O.: The Effects of Nano-Curcumin Supplementation on Risk Factors for Cardiovascular Disease: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials. Antioxidants (Basel). 10, 1015 (2021). https://doi.org/10.3390/antiox10071015
36. Chen, Y., Wu, Q., Zhang, Z., Yuan, L., Liu, X., Zhou, L.: Preparation of Curcumin-Loaded Liposomes and Evaluation of Their Skin Permeation and Pharmacodynamics. Molecules. 17, 5972–5987 (2012). https://doi.org/10.3390/molecules17055972
37. Bakun, P., Mlynarczyk, D.T., Koczorowski, T., Cerbin-Koczorowska, M., Piwowarczyk, L., Kolasiński, E., Stawny, M., Kuźmińska, J., Jelińska, A., Goslinski, T.: Tea-break with epigallocatechin gallate derivatives – Powerful polyphenols of great potential for medicine. European Journal of Medicinal Chemistry. 261, 115820 (2023). https://doi.org/10.1016/j.ejmech.2023.115820
38. Legeay, S., Rodier, M., Fillon, L., Faure, S., Clere, N.: Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome. Nutrients. 7, 5443–5468 (2015). https://doi.org/10.3390/nu7075230
39. Bouyahya, A., Balahbib, A., Khalid, A., Makeen, H.A., Alhazmi, H.A., Albratty, M., Hermansyah, A., Ming, L.C., Goh, K.W., El Omari, N.: Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus. Heliyon. 10, e29718 (2024). https://doi.org/10.1016/j.heliyon.2024.e29718
40. Fatima, N., Baqri, S.S.R., Bhattacharya, A., Koney, N.K.-K., Husain, K., Abbas, A., Ansari, R.A.: Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy. Front. Genet. 12, (2021). https://doi.org/10.3389/fgene.2021.758733
41. Aghababaei, F., Hadidi, M.: Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals (Basel). 16, 1020 (2023). https://doi.org/10.3390/ph16071020
42. Ferreira-Silva, M., Faria-Silva, C., Carvalheiro, M.C., Simões, S., Marinho, H.S., Marcelino, P., Campos, M.C., Metselaar, J.M., Fernandes, E., Baptista, P.V., Fernandes, A.R., Corvo, M.L.: Quercetin Liposomal Nanoformulation for Ischemia and Reperfusion Injury Treatment. Pharmaceutics. 14, 104 (2022). https://doi.org/10.3390/pharmaceutics14010104
43. Mahadev, M., Nandini, H.S., Ramu, R., Gowda, D.V., Almarhoon, Z.M., Al-Ghorbani, M., Mabkhot, Y.N.: Fabrication and Evaluation of Quercetin Nanoemulsion: A Delivery System with Improved Bioavailability and Therapeutic Efficacy in Diabetes Mellitus. Pharmaceuticals (Basel). 15, 70 (2022). https://doi.org/10.3390/ph15010070
44. Zhao, F.-Q., Wang, G.-F., Xu, D., Zhang, H.-Y., Cui, Y.-L., Wang, Q.-S.: Glycyrrhizin mediated liver-targeted alginate nanogels delivers quercetin to relieve acute liver failure. International Journal of Biological Macromolecules. 168, 93–104 (2021). https://doi.org/10.1016/j.ijbiomac.2020.11.204
45. Nouri, Z., Fakhri, S., El-Senduny, F.F., Sanadgol, N., Abd-ElGhani, G.E., Farzaei, M.H., Chen, J.-T.: On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective. Biomolecules. 9, 690 (2019). https://doi.org/10.3390/biom9110690
46. Vásquez-Reyes, S., Bernal-Gámez, M., Domínguez-Chávez, J., Mondragón-Vásquez, K., Sánchez-Tapia, M., Ordaz, G., Granados-Portillo, O., Coutiño-Hernández, D., Barrera-Gómez, P., Torres, N., Tovar, A.R.: The Effects of Novel Co-Amorphous Naringenin and Fisetin Compounds on a Diet-Induced Obesity Murine Model. Nutrients. 16, 4425 (2024). https://doi.org/10.3390/nu16244425
47. Murugesan, N., Woodard, K., Ramaraju, R., Greenway, F.L., Coulter, A.A., Rebello, C.J.: Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study. J Med Food. 23, 343–348 (2020). https://doi.org/10.1089/jmf.2019.0216
48. Parseghian, L., Kahrarian, N., Arabanian, A.S., Moradi Alvand, Z., Massudi, R., Rahimi, M., Rafati, H.: Berberine-loaded nanoemulsions as a natural food preservative; the impact of femtosecond laser irradiation on the antibacterial activity. Heliyon. 10, e37283 (2024). https://doi.org/10.1016/j.heliyon.2024.e37283
49. Ome, A.-S., G, M.: Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. Neurochemical research. 48, (2023). https://doi.org/10.1007/s11064-023-03983-z
50. Shuba, Y.M.: Beyond Neuronal Heat Sensing: Diversity of TRPV1 Heat-Capsaicin Receptor-Channel Functions. Front. Cell. Neurosci. 14, (2021). https://doi.org/10.3389/fncel.2020.612480

51. Ai, X., Yu, P., Peng, L., Luo, L., Liu, J., Li, S., Lai, X., Luan, F., Meng, X.: Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. Front. Pharmacol. 12, (2021). https://doi.org/10.3389/fphar.2021.762654
52. Li, A., Liu, Q., Li, Q., Liu, B., Yang, Y., Zhang, N.: Berberine Reduces Pyruvate-driven Hepatic Glucose Production by Limiting Mitochondrial Import of Pyruvate through Mitochondrial Pyruvate Carrier 1. EBioMedicine. 34, 243–255 (2018). https://doi.org/10.1016/j.ebiom.2018.07.039
53. Yin, J., Ye, J., Jia, W.: Effects and mechanisms of berberine in diabetes treatment. Acta Pharmaceutica Sinica B. 2, 327–334 (2012). https://doi.org/10.1016/j.apsb.2012.06.003
54. Sardana, S., Gupta, R., Madan, K., Bisht, D., Rana, V.S., Bhargava, S., Sethiya, N.K.: Advance drug delivery and combinational drug approaches for hepatoprotective action of berberine: a progressive overview with underlying mechanism. RPS Pharmacy and Pharmacology Reports. 2, rqad002 (2023). https://doi.org/10.1093/rpsppr/rqad002
55. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
56. DasNandy, A., Virge, R., Hegde, H.V., Chattopadhyay, D.: A review of patent literature on the regulation of glucose metabolism by six phytocompounds in the management of diabetes mellitus and its complications. Journal of Integrative Medicine. 21, 226–235 (2023). https://doi.org/10.1016/j.joim.2023.02.003
57. Ahmad, K., Shaikh, S., Lim, J.H., Ahmad, S.S., Chun, H.J., Lee, E.J., Choi, I.: Therapeutic application of natural compounds for skeletal muscle-associated metabolic disorders: A review on diabetes perspective. Biomedicine & Pharmacotherapy. 168, 115642 (2023). https://doi.org/10.1016/j.biopha.2023.115642
58. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
59. Atangwho, I.J., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discover Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
60. Maliszewska, K., Kretowski, A.: Brown Adipose Tissue and Its Role in Insulin and Glucose Homeostasis. Int J Mol Sci. 22, 1530 (2021). https://doi.org/10.3390/ijms22041530
61. Orji, U.O., Ibiam ,Udu Ama, Awoke ,Joshua Nonso, Atoki ,Ayomide Victor, Eze ,Ejike Daniel, Obasi ,Otuomasiri Divine, et al.: Ethanolic extract of Cnidoscolus aconitifolius leaves alleviates insulin resistance by modulating oxidative stress and inflammation in albino rats exposed to heavy metal mixture. Natural Product Research. 0, 1–14. https://doi.org/10.1080/14786419.2025.2478654

CITE AS: Nasira A. Sitar (2025). Browning of White Adipose Tissue by Natural Compounds: Implications for Obesity-Driven Type 2 Diabetes. IAA Journal of Biological Sciences 13(2):111-118. https://doi.org/10.59298/IAAJB/2025/132111118